Cardiac arrhythmia is cause by the presence of an ectopic focus or a re-entry mechanism where an action potential is delayed for some reason and enters nearby muscle fibres that are no longer refractory causing depolarisation and establishing a circuit movement.
There are three classes of anti-arrhythmic drugs which block sodium channels:
Class IA drugs block open Na+ sodium and can increase the effective refractory period. They produce a frequency-dependent block As they dissociate slowly away from these Na+ channels, they can prevent the Na+ channel from contributing towards an action potential if the frequency is high. Disopyramide one such example. It is used to treat ventricular arrhythmia by resulting in a negative inotropic effect.
Class IB drugs block closed Na+ sodium. It is often used to treat ventricular arrhythmia after an acute myocardial infraction. Lidocaine is one such example. It has little effect on normal cardiac tissues as it dissociates quickly from the Na+ channels. However, many Na+ channels are closed in ischemic cases due to anoxia. Lidocaine can hence act on these closed Na+ channels.
Class IC drugs are the most potent when it comes to blocking Na+ channels. They slowly dissociate from the Na+ channels and it leads to depressed conduction in the myocardium. These agents can prolong the RP and QRS intervals. Flecainide is one such example and it is used the treat atrial fibrillation.
No, Amlovasc tablets containing 10 mg of amlodipine are not beta blockers. Amlodipine is a calcium channel blocker used to treat high blood pressure and chest pain (angina) by relaxing blood vessels and increasing blood flow. Beta blockers, on the other hand, work by blocking the effects of adrenaline on the heart, reducing heart rate and blood pressure. It is important to differentiate between these two classes of medications for appropriate treatment and management of cardiovascular conditions.
Most people who have mitral valve prolapse do not require treatment or any lifestyle changes. It is not a life-threatening disease, but regular check-ups with your physician are advised. In most cases, limiting stimulants such as caffeine or cigarettes is all that is needed to control symptoms. Specific treatment for MVP is generally based on the patient’s overall health and medical history, extent of the disease, signs and symptoms. Treatments may include beta blockers or blood thinners, anticoagulants, adequate hydration, support stockings or surgery.
isn't it channel 32
GEC stands for General Entertainment Channel.
In Greece we have Nickelodeon and Channel 9.
Calcium channel blockers work by blocking calcium ion channels in cardiac and smooth muscle cells, leading to relaxation of blood vessels and decreased heart rate and force of contraction. This ultimately results in decreased blood pressure and improved blood flow. These medications are commonly used to treat conditions such as hypertension, angina, and certain cardiac arrhythmias.
Grapefruit juice may increase the effects of some calcium channel blockers.
The effects of taking calcium channel blockers during pregnancy have not been studied in humans.
Calcium channel blockers are available only with a physician's prescription and are sold in tablet, capsule, and injectable forms.
No, side effects of calcium channel blockers do not contain hair loss.
Calcium channel blockers are medicines that slow the movement of calcium into the cells of the heart and blood vessels.
Digitalis heart medicines: Taking these medicines with calcium channel blockers may increase the action of the heart medication.
A calcium channel blocker is a drug that lowers blood pressure by either preventing calcium from entering cells of the cardiac muscle, or the smooth muscle cells of the blood vessel walls.
no
Nifedipine.
Calcium channel blockers will not cure high blood pressure, but will help to control the condition.
The discovery of calcium channel blockers is attributed to two scientists, Albrecht Fleckenstein and Wilhelm Siegmund. Fleckenstein first characterized the mechanism of action of calcium channel blockers in the 1960s, while Siegmund later identified verapamil as the first calcium channel blocker used clinically.